Maria Pernemalm

About me
Publications
CV
Public outreach and news

About me

The analysis of human blood plasma with modern -omics technologies holds an
enormous potential to reveal biomarkers for diagnosis and treatment
selection, as well as studying complex systemic signalling events that are
involved in immune modulation, metastatic spread and disease progression.
My primary research interest is exploring how events on tissue and cellular
level are reflected on the molecular level in human blood plasma and how
these can be monitored using -omics methods. I have a long-standing interest
and expertise in method development for mass spectrometry (MS) based plasma
proteomics and in combining different analytical approaches and data sources
with the aim to improve the understanding of the dynamics in the plasma
proteome, in particularly related to biomarker discovery in lung cancer and
malignant melanoma.
The plasma team works both on method development and applied projects
involving expanded applications of plasma proteome analysis such as plasma
protein interaction with viruses and nanoparticles, proteogenomics biomarker
discovery, and approaches to combine biochemical plasma markers with symptoms
clusters for improved accuracy and sensitivity in precision medicine.
*2022* Associate professor in Medical Proteomics, KI, Dept. Oncology
Pathology
*2009* PhD KI, Dept. Oncology Pathology
*2010-2011* KI, Dept. Oncology Pathology, Post Doc
*2011-2012* Scilifelab/KI/Dept. Oncology Pathology, Post Doc
*2012-2013* The University of Manchester, Stem cell &
leukemia proteomics
lab, Post Doc
*2013-2014* Scilifelab/KI/Dept. Oncology Pathology, Post Doc
*2014-* Scilifelab/KI/Dept. Oncology Pathology, Assistant professor

Articles

Article: NATURE COMMUNICATIONS. 2023;14(1):5921

Comprehensive proteomics and meta-analysis of COVID-19 host response.

Babačić H; Christ W; Araújo JE; Mermelekas G; Sharma N; Tynell J; García M; Varnaite R; Asgeirsson H; Glans H; Lehtiö J; Gredmark-Russ S; Klingström J; Pernemalm M
Article: RESPIRATORY RESEARCH. 2023;24(1):62

Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia.

Palma Medina LM; Babačić H; Dzidic M; Parke Å; Garcia M; Maleki KT; Unge C; Lourda M; Kvedaraite E; Chen P; Muvva JR; Cornillet M; Emgård J; Moll K; Karolinska K. I./K. COVID-19 Study Group; Michaëlsson J; Flodström-Tullberg M; Brighenti S; Buggert M; Mjösberg J; Malmberg K-J; Sandberg JK; Gredmark-Russ S; Rooyackers O; Svensson M; Chambers BJ; Eriksson LI; Pernemalm M; Björkström NK; Aleman S; Ljunggren H-G; Klingström J; Strålin K; Norrby-Teglund A
Article: MOLECULAR ONCOLOGY. 2023;17(2):238-260

Glioblastoma stem cells express non-canonical proteins and exclusive mesenchymal-like or non-mesenchymal-like protein signatures.

Babačić H; Galardi S; Umer HM; Hellström M; Uhrbom L; Maturi N; Cardinali D; Pellegatta S; Michienzi A; Trevisi G; Mangiola A; Lehtiö J; Ciafrè SA; Pernemalm M
Article: FRONTIERS IN ENDOCRINOLOGY. 2022;13:971313

Proteome profiling of whole plasma and plasma-derived extracellular vesicles facilitates the detection of tissue biomarkers in the non-obese diabetic mouse.

Diaz Lozano IM; Sork H; Stone VM; Eldh M; Cao X; Pernemalm M; Gabrielsson S; Flodström-Tullberg M
Article: JOURNAL OF PROTEOME RESEARCH. 2021;20(9):4610-4620

Evaluation of Spin Columns for Human Plasma Depletion to Facilitate MS-Based Proteomics Analysis of Plasma.

Cao X; Sandberg A; Araújo JE; Cvetkovski F; Berglund E; Eriksson LE; Pernemalm M
Article: NEOPLASIA. 2021;23(8):783-791

Plasma proteome alterations by MAPK inhibitors in BRAFV600-mutated metastatic cutaneous melanoma.

Babačić H; Eriksson H; Pernemalm M
Article: JOURNAL OF EXTRACELLULAR VESICLES. 2021;10(9):e12128

Molecular evaluation of five different isolation methods for extracellular vesicles reveals different clinical applicability and subcellular origin.

Veerman RE; Teeuwen L; Czarnewski P; Güclüler Akpinar G; Sandberg A; Cao X; Pernemalm M; Orre LM; Gabrielsson S; Eldh M
Article: MOLECULAR ONCOLOGY. 2021;15(2):429-461

High-throughput proteomics of breast cancer interstitial fluid: identification of tumor subtype-specific serologically relevant biomarkers.

Terkelsen T; Pernemalm M; Gromov P; Børresen-Dale A-L; Krogh A; Haakensen VD; Lethiö J; Papaleo E; Gromova I
Article: JOURNAL FOR IMMUNOTHERAPY OF CANCER. 2020;8(1):e000204

In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.

Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
Article: FRONTIERS IN ONCOLOGY. 2020;10:51

Immunometabolic Network Interactions of the Kynurenine Pathway in Cutaneous Malignant Melanoma.

Rad Pour S; Morikawa H; Kiani NA; Gomez-Cabrero D; Hayes A; Zheng X; Pernemalm M; Lehtiö J; Mole DJ; Hansson J; Eriksson H; Tegnér J
Article: SCIENTIFIC REPORTS. 2019;9(1):16504

Early symptoms and sensations as predictors of lung cancer: a machine learning multivariate model.

Levitsky A; Pernemalm M; Bernhardson B-M; Forshed J; Kölbeck K; Olin M; Henriksson R; Lehtiö J; Tishelman C; Eriksson LE
Article: JOURNAL OF PROTEOME RESEARCH. 2019;18(9):3369-3382

Identification of a Biomarker Panel for Early Detection of Lung Cancer Patients.

Geary B; Walker MJ; Snow JT; Lee DCH; Pernemalm M; Maleki-Dizaji S; Azadbakht N; Apostolidou S; Barnes J; Krysiak P; Shah R; Booton R; Dive C; Crosbie PA; Whetton AD
Article: NATURE COMMUNICATIONS. 2019;10(1):2331

The viral protein corona directs viral pathogenesis and amyloid aggregation.

Ezzat K; Pernemalm M; Pålsson S; Roberts TC; Järver P; Dondalska A; Bestas B; Sobkowiak MJ; Levänen B; Sköld M; Thompson EA; Saher O; Kari OK; Lajunen T; Sverremark Ekström E; Nilsson C; Ishchenko Y; Malm T; Wood MJA; Power UF; Masich S; Lindén A; Sandberg JK; Lehtiö J; Spetz A-L; El Andaloussi S
Article: CLINICAL CANCER RESEARCH. 2019;25(10):3115-3127

Ultrasensitive Immunoprofiling of Plasma Extracellular Vesicles Identifies Syndecan-1 as a Potential Tool for Minimally Invasive Diagnosis of Glioma.

Indira Chandran V; Welinder C; Månsson A-S; Offer S; Freyhult E; Pernemalm M; Lund SM; Pedersen S; Lehtiö J; Marko-Varga G; Johansson MC; Englund E; Sundgren PC; Belting M
Article: ELIFE. 2019;8:e41608

In-depth human plasma proteome analysis captures tissue proteins and transfer of protein variants across the placenta.

Pernemalm M; Sandberg A; Zhu Y; Boekel J; Tamburro D; Schwenk JM; Björk A; Wahren-Herlenius M; Åmark H; Östenson C-G; Westgren M; Lehtiö J
Article: CELL DEATH & DISEASE. 2017;8(8):e3029

Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.

Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Article: INTERNATIONAL JOURNAL OF CANCER. 2016;138(12):2984-2992

Protein Z: A putative novel biomarker for early detection of ovarian cancer.

Russell MR; Walker MJ; Williamson AJK; Gentry-Maharaj A; Ryan A; Kalsi J; Skates S; D'Amato A; Dive C; Pernemalm M; Humphryes PC; Fourkala E-O; Whetton AD; Menon U; Jacobs I; Graham RLJ
Article: BMJ OPEN RESPIRATORY RESEARCH. 2016;3(1):e000114

ERK and AKT phosphorylation status in lung cancer and emphysema using nanocapillary isoelectric focusing.

Crosbie PAJ; Crosbie EJ; Aspinall-O'Dea M; Walker M; Harrison R; Pernemalm M; Shah R; Joseph L; Booton R; Pierce A; Whetton AD
Article: EBIOMEDICINE. 2015;2(8):841-850

Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value.

Walker MJ; Zhou C; Backen A; Pernemalm M; Williamson AJK; Priest LJC; Koh P; Faivre-Finn C; Blackhall FH; Dive C; Whetton AD
Article: PLOS ONE. 2015;10(10):e0129008

Proteomics Analysis Reveals Distinct Corona Composition on Magnetic Nanoparticles with Different Surface Coatings: Implications for Interactions with Primary Human Macrophages.

Vogt C; Pernemalm M; Kohonen P; Laurent S; Hultenby K; Vahter M; Lehtiö J; Toprak MS; Fadeel B
Article: BIOMED RESEARCH INTERNATIONAL. 2015;2015:462549-13

Identifying and Assessing Interesting Subgroups in a Heterogeneous Population.

Lee W; Alexeyenko A; Pernemalm M; Guegan J; Dessen P; Lazar V; Lehtiö J; Pawitan Y
Article: PLOS ONE. 2015;10(5):e0126472

Differential protein expression profiles of cyst fluid from papillary thyroid carcinoma and benign thyroid lesions.

Dinets A; Pernemalm M; Kjellin H; Sviatoha V; Sofiadis A; Juhlin CC; Zedenius J; Larsson C; Lehtiö J; Höög A
Article: BRITISH JOURNAL OF CANCER. 2014;110(10):2489-2495

Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance.

Azimi A; Pernemalm M; Frostvik Stolt M; Hansson J; Lehtiö J; Egyházi Brage S; Hertzman Johansson C
Article: JOURNAL OF PROTEOME RESEARCH. 2013;12(9):3934-3943

Quantitative proteomics profiling of primary lung adenocarcinoma tumors reveals functional perturbations in tumor metabolism.

Pernemalm M; De Petris L; Branca RM; Forshed J; Kanter L; Soria J-C; Girard P; Validire P; Pawitan Y; van den Oord J; Lazar V; Påhlman S; Lewensohn R; Lehtiö J
Article: JOURNAL OF PROTEOME RESEARCH. 2013;12(2):1014-1019

A novel prefractionation method combining protein and peptide isoelectric focusing in immobilized pH gradient strips.

Pernemalm M; Lehtiö J
Article: METHODS IN MOLECULAR BIOLOGY. 2013;1023:3-11

Narrow-range peptide isoelectric focusing as peptide prefractionation method prior to tandem mass spectrometry analysis.

Pernemalm M
Article: BMC BIOINFORMATICS. 2012;13:226

Network enrichment analysis: extension of gene-set enrichment analysis to gene networks.

Alexeyenko A; Lee W; Pernemalm M; Guegan J; Dessen P; Lazar V; Lehtiö J; Pawitan Y
Article: MOLECULAR & CELLULAR PROTEOMICS. 2011;10(10):M111.010264

Enhanced information output from shotgun proteomics data by protein quantification and peptide quality control (PQPQ).

Forshed J; Johansson HJ; Pernemalm M; Branca RMM; Sandberg A; Lehtiö J
Article: PROTEOME SCIENCE. 2010;8:9

A novel method for sample preparation of fresh lung cancer tissue for proteomics analysis by tumor cell enrichment and removal of blood contaminants.

De Petris L; Pernemalm M; Elmberger G; Bergman P; Orre L; Lewensohn R; Lehtiö J
Article: PROTEOMICS. 2009;9(13):3414-3424

Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion.

Pernemalm M; De Petris L; Eriksson H; Brandén E; Koyi H; Kanter L; Lewensohn R; Lehtiö J
Article: LUNG CANCER. 2009;63(3):410-417

Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.

De Petris L; Orre LM; Kanter L; Pernemalm M; Koyi H; Lewensohn R; Lehtiö J
Article: JOURNAL OF PROTEOME RESEARCH. 2008;7(7):2712-2722

Evaluation of three principally different intact protein prefractionation methods for plasma biomarker discovery.

Pernemalm M; Orre LM; Lengqvist J; Wikström P; Lewensohn R; Lehtiö J
Article: JOURNAL OF PROTEOME RESEARCH. 2008;7(6):2332-2341

Proteomic data analysis workflow for discovery of candidate biomarker peaks predictive of clinical outcome for patients with acute myeloid leukemia.

Forshed J; Pernemalm M; Tan CS; Lindberg M; Kanter L; Pawitan Y; Lewensohn R; Stenke L; Lehtiö J
Article: MOLECULAR & CELLULAR PROTEOMICS. 2007;6(12):2122-2131

Up-regulation, modification, and translocation of S100A6 induced by exposure to ionizing radiation revealed by proteomics profiling.

Orre LM; Pernemalm M; Lengqvist J; Lewensohn R; Lehtiö J
Article: PROTEOMICS. 2006;6(23):6124-6133

Annotated regions of significance of SELDI-TOF-MS spectra for detecting protein biomarkers.

Tan CS; Ploner A; Quandt A; Lehtiö J; Pernemalm M; Lewensohn R; Pawitan Y
Show more

All other publications

Review: JOURNAL OF PROTEOME RESEARCH. 2021;20(12):5241-5263

Advances and Utility of the Human Plasma Proteome.

Deutsch EW; Omenn GS; Sun Z; Maes M; Pernemalm M; Palaniappan KK; Letunica N; Vandenbrouck Y; Brun V; Tao S-C; Yu X; Geyer PE; Ignjatovic V; Moritz RL; Schwenk JM
Review: CANCER TREATMENT REVIEWS. 2015;41(4):361-375

Molecular histology of lung cancer: from targets to treatments.

Wood SL; Pernemalm M; Crosbie PA; Whetton AD
Review: EXPERT REVIEW OF PROTEOMICS. 2014;11(4):431-448

Mass spectrometry-based plasma proteomics: state of the art and future outlook.

Pernemalm M; Lehtiö J
Review: CANCER TREATMENT REVIEWS. 2014;40(4):558-566

The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets.

Wood SL; Pernemalm M; Crosbie PA; Whetton AD
Review: PROTEOMICS. 2009;9(6):1420-1427

Affinity prefractionation for MS-based plasma proteomics.

Pernemalm M; Lewensohn R; Lehtiö J
Meeting abstract: JOURNAL OF THORACIC ONCOLOGY. 2007;2(8):S356-S357

Mass spectrometry profiling of low molecular weight platelet Proteome for the detection of lung cancer specific biomarkers

De Petris L; Pernemalm M; Branden E; Koyi H; Forshed J; Sundelin B; Lewensohn R; Lehtio J

Employments

Principal Researcher, Department of Oncology-Pathology, Karolinska Institutet, 2022-

Degrees and Education

Docent, Karolinska Institutet, 2022
Degree Of Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 2009
Master Of Medical Science, Karolinska Institutet, 2005

About me

Articles

All other publications

Employments

Degrees and Education

News from KI

Events from KI